Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06804785

Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

Status
Recruiting
Phase
Study type
Observational
Enrollment
800 (estimated)
Sponsor
Northwestern University · Academic / Other
Sex
Male
Age
18 Years – 89 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. The goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as biopsies.

Detailed description

The overall goal of this project is to create a diagnosis and patient management strategy (called HIT-PIRADS) for prostate cancer (PCa) that will significantly increase positive predictive value (PPV) for clinically significant PCa detection while minimizing unnecessary prostate biopsies and related morbidities. Due to its interpretable nature and bias correction paradigm, the AI system will generate predictions that physicians can trust. One of the immediate outcomes of the system will be a reproducible risk scoring system that can be used in community hospitals and locales without MRI-subspeciality genitourinary trained radiologists to improve the accuracy of prostate imaging nationwide. In the long term, the investigators expect HIT-PIRADS to be widely adopted in clinics and trigger other treatment and prevention strategies to be developed based on HIT-PIRADS.

Conditions

Timeline

Start date
2025-08-01
Primary completion
2027-05-01
Completion
2028-05-01
First posted
2025-02-03
Last updated
2025-05-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06804785. Inclusion in this directory is not an endorsement.